Good news - looks like we missed topline by a hair and hit some of the secondaries.  Both CVD and CKD embargoed til AHA, so data on both presented there (IMO).  According to don, lowish possiblity of going for approval with current data but strong possibility of adding data to BoM (funded with JV partner) to shore up the evidence.  Lot riding on that Nov. 13 FDA meeting - go RVX team!

Jupe

Perhaps Bear can figure out the most likely March conference that the steering committee wanted some of the results to presented at?